Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Debt Repayments (2022 - 2025)

Cytek Biosciences (CTKB) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments rose 2015.11% year-over-year to $2.9 million, compared with a TTM value of $4.7 million through Dec 2025, up 751.89%, and an annual FY2025 reading of $4.7 million, up 751.89% over the prior year.
  • Long-Term Debt Repayments was $2.9 million for Q4 2025 at Cytek Biosciences, up from $145000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.9 million in Q4 2025 and bottomed at $50000.0 in Q4 2022.
  • Average Long-Term Debt Repayments over 4 years is $455153.8, with a median of $140000.0 recorded in 2023.
  • The sharpest move saw Long-Term Debt Repayments decreased 4.79% in 2024, then soared 2015.11% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $50000.0 in 2022, then soared by 180.0% to $140000.0 in 2023, then decreased by 0.71% to $139000.0 in 2024, then skyrocketed by 2015.11% to $2.9 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for CTKB at $2.9 million in Q4 2025, $145000.0 in Q3 2025, and $142000.0 in Q2 2025.